EXPAREL Case Studies
Read a review discussing the role of EXPAREL as the foundation of a multimodal approach to pain management in two case studies. >
A Multimodal Approach to Postsurgical Pain
The Joint Commission recommends an individualized, multimodal plan to manage postsurgical pain.3 Find out how a single administration of non-opioid EXPAREL® provides analgesia with reduced opioid requirements.1,2
Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and hemorrhoidectomy procedures.
To report an adverse event, e-mail drugsafety@pacira.com or dial 1-855-RX-EXPAREL (1-855-793-9727).
For medical inquiries related to EXPAREL, contact Medical Information at medinfo@pacira.com or 1-855-RX-EXPAREL (1-855-793-9727).
EXPAREL Administration
Learn how clinicians are infiltrating EXPAREL in a variety of procedures.
Sign Up
Sign up to receive updates on EXPAREL.
These are not all of the potential important safety considerations for EXPAREL, please see the full Prescribing Information.
References:
- EXPAREL [prescribing information]. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; 2011.
- Gorfine SR, Onel E, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Diseases of the Colon & Rectum. 2011;54(12):1552-1559.
- Safe Use of Opioids. The Joint Commission Sentinel Event Alert. Issue 49; August 8, 2013.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.
Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.
Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.
In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for EXPAREL.
